Study for efficacy of DPP-4 inhibitor to mytonic dystrophy complicated diabetes mellitus by continuous glucose monitoring (CGM)
Not Applicable
- Conditions
- Myotonic dystrophy type 1
- Registration Number
- JPRN-UMIN000017798
- Lead Sponsor
- Dystrophia Myotonica: Clinical Treatment Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1.Medicated by insulin, DPP-4 inhibitor or GLP-1 agonist 2.Serious infection, perioperative or serious injury 3.Cardio-vascular event 4.Proronged QT on ECG 5.Serious liver damage 6.Moderate or serious renal damage 7.Moderate or serious heart failure 8.Gestation or lactation period 9.Short bowel syndrome 10.Medicated by steroid, interferon, hormonal agent, atypical antipsychotic, IA antiarrhythmic agent or III antiarrhythmic agent 11.Emaciation or skin disease with difficulty to be attached CGM 12.No informed consent with a form 13.Assessed as inadequate by a physician in charge
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation before and after administration of DPP-4 inhibitor. Index by CGM (mean blood sugar (BS), SD of BS, M value, MAGE, BS area, proportion of hypoglycemia or hyperglycemia) and routine blood examination.
- Secondary Outcome Measures
Name Time Method Adverse event